Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
about
BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking.Active and passive immunization for cancerBacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literatureThe Role of Toll-Like Receptors in Hematopoietic MalignanciesThe intestinal microbiome and surgical disease.Combined treatment with anticancer vaccine using genetically modified endothelial cells and imatinib in bladder cancer.Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8.Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancerIdentification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A.Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosisDetection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications.Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and CancerGenetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence.Is intravesical chemotherapy for superficial bladder cancer still justified?Immunological basis in the pathogenesis and treatment of bladder cancerTLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinomaThe association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytesRecent improvements in the detection and treatment of nonmuscle-invasive bladder cancer.Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy.Superficial bladder cancer: part 2. Management.Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer.Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder CancerSystemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies.Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma.Gasotransmitters in cancer: from pathophysiology to experimental therapy.Bilateral panuveitis following intravesical BCG immunotherapy for bladder carcinoma.Developments in intravesical therapy for non-muscle-invasive bladder cancer.Diagnosis and management of urothelial carcinoma of the bladder.Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.BCG response prediction with cytokine gene variants and bladder cancer: where we are?Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
P2860
Q24816183-B84C785B-3764-42F3-B0C7-4033F021913CQ27015783-41222961-9C97-44DF-976C-0584FDFC8BF9Q27021357-3A816478-90A1-42F9-BF47-944DAF16252FQ28077740-4FF7C7CF-D0D9-4826-849C-78418046BF3AQ30248605-96F662DA-54B8-4431-B315-AE06F93975D5Q30431866-B0C653C7-4047-47BA-8A9E-4FFA0F563774Q34111796-575E9E35-3583-425C-AB08-6466B3FC2D1CQ34203675-0D52F42D-AE7A-4E88-A06E-B84E3468B33AQ34409699-A27107DF-DFF8-4121-88C6-193A9956B40BQ34988147-B3809CFF-4E0B-4FEC-922D-8FD79291F38BQ35067132-34C02BE8-B618-4EEB-A4FC-F1413E700E5BQ35826408-A5AF079D-DCD6-418B-A383-A3E12041FAD3Q35853865-4997D91A-91E4-4990-B92E-463E8C0F5F1FQ36070462-2B64DA49-CAB6-4C6E-9A46-8362738B5A16Q36127825-B491FA96-E8F6-4262-B20A-7E6F485F029FQ36137539-A4C53731-8EDC-4B3D-8B97-17A7C87CB0A4Q36142577-63E9291C-C23C-4702-924B-480AE9805664Q36249221-B82F7C1E-5C0F-4177-A1F9-F140380EE023Q36253605-A1FC3588-62B3-4B10-9051-F41CB0259F4DQ36260118-0DBD0FB2-0A8F-4035-B9CF-571AF2DF1938Q36343879-4054C419-DC57-4104-8D57-C63612076A64Q36480350-5DA499AD-AEF4-4A36-B2C9-7B4A37144657Q36522523-6A5282F2-331B-4CA9-85C6-0056845406EDQ36614005-A4894B8F-FC3C-4EF6-8107-9B06AB9694E7Q36663422-AE7FB6F1-AE82-4B3B-A969-AC0508DE09E6Q36788508-30FE093D-11DE-492C-8DDB-BF8A075D15D2Q36813961-6E0332A3-4F62-49FE-BDA2-5005BBEAA6D8Q36839682-BFF9CB7C-5AF6-407E-B3E0-07CA6431B873Q36939977-769DBE10-E1D3-42CC-9A8D-D8BB1271F01FQ37051022-590E2838-0534-4242-AB0B-E4BFABE2B498Q37423131-BB12CD0F-E470-41B1-B283-7643C208217CQ37457553-5630ABFD-0525-418A-A4F9-2069494D74C4Q37482664-7B307E8C-A0C2-4228-A53C-6F0C09FF111EQ37656625-7692B448-E6C5-4F4D-8BD4-1DE714F3DE1CQ37775976-08A35D15-55AF-4C1F-802A-96C392F33145Q37812604-032E55E0-FECB-4C5C-812C-9C9A59FFB150Q37874887-E7F6592E-80AE-4BB3-8A9B-DDC87F94EDACQ37894687-4D2D5452-8454-441A-B7F5-B4A3CA54822BQ37935658-B700943E-40DA-4D0B-B140-FFB701597DA6Q38078886-FB33C943-D963-405C-93FE-D269C01E16B8
P2860
Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Immune mechanisms in bacillus ...... or superficial bladder cancer.
@ast
Immune mechanisms in bacillus ...... or superficial bladder cancer.
@en
type
label
Immune mechanisms in bacillus ...... or superficial bladder cancer.
@ast
Immune mechanisms in bacillus ...... or superficial bladder cancer.
@en
prefLabel
Immune mechanisms in bacillus ...... or superficial bladder cancer.
@ast
Immune mechanisms in bacillus ...... or superficial bladder cancer.
@en
P1476
Immune mechanisms in bacillus ...... for superficial bladder cancer
@en
P2093
Andreas Böhle
P304
P356
10.1097/01.JU.0000073852.24341.4A
P407
P50
P577
2003-09-01T00:00:00Z